

10 May 2017

Company Announcements Office Australian Securities Exchange

Issue of Shares

Xref Limited (ASX:XF1) advises that, in consideration for the payment of the purchase price of the domain name xref.com for a price of US\$75,000, as detailed in the announcement made earlier today, it has now issued 200,554 fully paid ordinary shares to the yendor.

An Appendix 3B for the issue of these shares is attached.

Xref Limited

Robert J Waring
Company Secretary

Cleansing Statement – Notice under Section 708A(5)(e)

As at 10 May 2017, Xref Limited gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

- 1. the Company issued the abovementioned securities without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2. the Company has complied with the provisions, as they apply to the Company, of Chapter 2M of the Corporations Act and with Section 674 of the Corporations Act: and
- 3. there is no information:
 - a. that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; or
 - b. that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of the assets and liabilities, financial performance, profits and losses and prospects of Xref Limited, or the rights and liabilities attaching to Xref Limited ordinary shares.

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o 1/07/96 \ Origin: Appendix 5 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 4/03/13 \ Amended o 1/07/98, o 1/09/99, o 1/07/00, 30/09/01, 11/03/02, o 1/01/03, 24/10/05, o 1/08/12, o 1/08/12$

Name of entity		
Xref Limited (ASX:XF1)		
ARBN		
122 404 666		
We (the entity) give ASX the following information.		
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).		
*Class of *securities issued or to be issued	Fully paid ordinary shares.	

Number of *securities issued or to be issued (if known) or maximum number which may be issued

200,554

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Issue of fully paid ordinary shares at the 15-day volume-weighted average price of A\$0.507.

04/03/2013 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

Do the *securities rank equally 4 in all respects from the +issue Yes, the securities rank equally with the date with an existing +class of Company's existing fully paid ordinary shares. quoted +securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Issue price or consideration US\$75,000 (being an exchange rate of 0.7376) i.e. A\$101,681. Refer attached cover letter. 6 Purpose of the issue (If issued as consideration for Consideration for the purchase of the the acquisition of assets, clearly domain name xref.com. identify those assets) Is the entity an +eligible entity 6a that has obtained security Yes holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder The Company received shareholder approval at resolution under rule 7.1A was passed its Annual General Meeting (AGM) held on 25 November 2016 under ASX Listing Rule 7.1A. 6c Number of *securities issued without security holder approval 200,554 under rule 7.1 6d Number of *securities issued with security holder approval None under rule 7.1A Number of *securities issued 6e with security holder approval under rule 7.3, or another None specific security holder approval (specify date of meeting)

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6f	Number of *securities issued under an exception in rule 7.2	None	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	29,391,673	
7	*Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	10 May 2017	
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	Number 53,675,869	⁺ Class Fully paid ordinary shares

o4/o3/2013 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)

* The conversion ratio of the Performance Rights into ordinary shares upon achievement of a relevant Performance Milestone is one ordinary share for each Performance Right. They are in escrow until 8 February 2018.

Number	+Class
64,893,591	Fully paid ordinary shares in escrow until 8 February 2018
16,666,667	A Class Performance Rights *
16,666,666	C Class Performance Rights *
4,508,909	Options – will expire, if not exercised, by 1 February 2019 – exercise price \$0.23, in escrow until 8 February 2018 (all of which have vested, except for 300,000 options)
7,000,000	Options – 4,500,000 of the Options will expire, if not exercised, by 25 November 2021 and 2,500,000 of the Options will expire, if not exercised, by 25 November 2022. All have an exercise price of A\$0.70.
900,000	Options – will expire, if not exercised, by 25 November 2021. All have an exercise price of A\$0.70.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

These fully paid ordinary shares have full participation in any future dividends.

Part 2 - Pro rata issue

Questions 11 to 33 are not applicable

Part 3 - Quotation of securities

 $You \ need \ only \ complete \ this \ section \ if \ you \ are \ applying \ for \ quotation \ of \ securities$

- Type of *securities (tick one)
- (a) +Securities described in Part 1
- (b) All other *securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to i	indicate	you are providing the information or documents
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

Questions 38 to 42 are not applicable

o4/o3/2013 Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Date: 10 May 2017

(Director/Company Secretary)

Print name:

Robert J Waring

== == == ==

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	90,273,668	
Add the following:		
Number of fully paid ⁺ ordinary securities issued in that 12-month period under an exception in rule 7.2	Nil	
Number of fully paid ⁺ ordinary securities issued in that 12-month period with shareholder approval	28,095,238	
Number of partly paid ⁺ ordinary securities that became fully paid in that 12-month period	Nil	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid †ordinary securities cancelled during that 12-month period		
"A"	118,368,906	

04/03/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	17,755,336
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rul
Insert number of ⁺ equity securities issued or agreed to be issued in that 12-month period <i>not counting</i> those issued:	
• Under an exception in rule 7.2	
• Under rule 7.1A	
 With security holder approval under rule 7.1 or rule 7.4 	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	200,554
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	17,755,336
Note: number must be same as shown in Step 2	
Subtract "C"	200,554
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	17,554,782
	[Note: this is the remaining placement capacity under rule 7.1]

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	118,368,906	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	11,836,891	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12-month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	NET.	
"E"	Nil	

o4/o3/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	11,836,891	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	11,836,891	
	Note: this is the remaining placement capacity under rule 7.1A	

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.